Non-Traditional Agents Defense (Applied Research)

Abstract

Project NT2 provides early applied research to enhance and develop defensive capabilities against Non-Traditional Agents (NTAs). This project focuses on expanding scientific knowledge required to develop defensive capabilities and to demonstrate fast and agile scientific responses to enhance or develop capabilities that address emerging threats. Efforts and studies conducted under this project address direction from the FDA to conduct specific post-New Drug Application (NDA)-approval efforts and studies (e.g. required studies, Post Marketing Commitments), and requirements from the joint service users. This project is a comprehensive and focused effort for developing Non-Traditional Agents (NTA) defense capabilities, coordinated with specific interagency partners for doctrine, equipment, and training for the Warfighter and civilian population for defense against NTAs. Individual efforts in this project include: - Support an integrated approach to counter emerging threats through innovative science and technology (S&T) solutions for detection, protection, decontamination, information systems and modeling and simulation, and medical countermeasures. - Provides for the upgrade and modernization of Medical Chemical Defense countermeasures which include U.S. Food and Drug Administration (FDA) approved prophylactics, pre-treatments, and therapeutics and intend to protect and/or sustain the Joint Service Member in a toxic chemical threat environment. Starting in FY21, an administrative change improving S&T budget agility and transition efficiency will merge NTA lines to RDT&E Projects Chemical Biological Defense (CB2) and Techbase Medical Defense (TM2).

Document Details

• Document Type: Project
• Publication Date: Oct 01, 2021
• Source ID: NT2_0602384BP_2_0400_PB_2021

Tags

Readers

• Critical Infrastructure Protection in CBRN and WMD Threats.